quarter delivered with achieving results. operational Good afternoon. quarter and of team great quarter by first INNOVATE his adjusted of start million. revenues $XX.X revenues and million delivered million Global and EBITDA XXXX. and DBM $XXX.X We million of $XX.X the adjusted of the XXXX Rustin strong of a of first had EBITDA strong at another $XXX.X financial to in
results year-over-year were we points to EBITDA was a driven growth, top to basis significant year expansion XXX line ago, flat experienced relatively of compared adjusted While by gross margin strong approximately XX.X%. which
billion remains EBITDA consideration takes DBM's year-over-year expanded quarter. which by points XX X.X% backlog, not total also Adjusted approximately awarded basis commercial into at first the to tight, in the of of end at Overall, although market level. adjusted high healthy a $X.X signed bidding contracts but margin yet first to quarter. a level remained the very the the activity of continue the at construction be sectors
of work both are in and This new the in will sectors and seeing piece surge beyond. we be numerous modularization activity industrial However, our a business XXXX meaningful in opportunities market. of
compared to Cherine from in Moving other another year the America the and of in record system quarter. for second the increase a quarter high RX XXX% in in grow gain the by period North achieved system the on quarter continued experiencing its business, XXX% Glacial of row. provider Dave of in year. single RX exciting yet treated America last during continued patients increase XX% average prior and team monthly East to quarter outside areas American sales utilization the a has same North of in another as had Life With traction. Sciences. in to their RX Middle per the launching in to product record-breaking RX and a continues North growth increase quarter. sales and growth
followers With across experienced the media and from board mentions to increases RX initiatives, social awareness focus a continued website on market traffic.
buyer qualified system interest, of have are note these opportunities increase led sales significant important it in XXXX. these indicators to to in is As initiatives a that clear
momentum beginning by in state-of-the-art are the momentum in has quarter. RX market technology, the is use the of to and encouraged continued to as build this demand into their We see second we expanded continue
their the for company to MediBeacon, kidney FDA. with At continues the work program substantive through review monitoring
in first As approval previously the an update move MediBeacon's interactively FDA in process. with resolve met explained, MediBeacon XXXX outstanding to second working to to hope provide We and status. the quarters of and is to on questions order
posted MediBeacon's the pivotal website call, clinicaltrials.gov As April mentioned on study were XX. on on our last results
on seen in kidney from CKD study.
We prior transdermal trends website, FDA endpoints by have recent measurement MediBeacon's great impact-chronic noted X established monitoring the starting primary forecasts predetermined the a in clinicaltrials.gov market that secondary for with the and opportunity of As market. real-time to across the disease studies XX.X% see to suffer the the acronym countries kidney and the CKD and of The number GFR system up we will the met population study or of function, XXXX.
recently of study and the World Nephrology. presented sponsored and significant in was CKD The the improvements management a CKD associated monitoring. Congress that concluded study with AstraZeneca reveal-CK diagnosis at record
positively with from Pharmaceutical R&D there approve are therapeutics kidney approximately assets of for pharmaceutical estimated agnostics a a like of practical GLP-X number assessment a kidney kidney development likely of that factors, is would growing and companies of clinically XXX the target that disease accurate indications. disease products increasing that an indications. early to are targets the provide range that that are addressable see ranging growth functions. impact chronic investments robust pipeline It We in nephrology Ozempic including to market
X to Outlaw quarter. quarter note, launches are XXXX and beginning new network delivered Spectrum January with the Of and driving growth, in $X.X revenue with network Free higher million TVs [indiscernible] first the team sports declined streaming held strong of XXX growing for networks of TV. SPORTS customers. EBITDA grew at existing launches rates emerged, X a subsequent churn over-the-air programmers distribution particularly revenues coverage. cable and for Network and launch network are Outdoor looking Pricing SPEED new MTRSPTX, as America, with networks. has and new
opportunities optimize in broadcast revenues. efforts broadcasting efforts X.X alternative revenue continue strategic like the providers equipment XG the At new and as technology participated Spectrum Las for share in X.X spectrum market believe considerable of leader conference, in broadcasting platform continued technologies our with the We robust we to which well XG April, Broadcast vendors NAB announced in with broadcasters. with revenue conference interest exploring given Broadcasting's generated applications.
And provide our HCX housing the in broadcasting. future light and agreements Vegas, from operating ATS opportunities to will large repurpose closely including Qualcomm, technology, work Public and in offer as and national distribution XG commercial And station other content we in to
levels with We a an all momentum are to combined robust and our segments approval OTA RX, encouraging growth in X the at as pipeline, operational very with and increase happy demand continues continue at progress MediBeacon FDA develop. results to high DBM next-gen perform at of on opportunities with of
we the the be of continue driver We highly price. underperformance our to in structure, stock focused believe on capital is our key which addressing
and we to businesses. upstream structure noncash our closed XXXX.
To with noncash subsidiaries, rights we our opportunities We debt our to believe capital end, now up to utilize for make address in continue to flowing have the exploring to set payments sufficient of that on created strategy flowing combined have assets company progress we our on refinance our cash a execute runway offering our our from and expectation
patient ensure on time of the these we remains that the for within maximize the focus these time. right being Exiting we have value Our value frame created assets. to businesses takes
market as a I'll with resolution the along to turn progress reach for of this in be the the and a M&A market it discussed year.
With overall to in positive optimistic our and that, structure. look build to on assets we hope momentum as over and continue We momentum We to in above. see these quarter the review financial second continue the surrounding and to capital remainder off indicators Mike XXXX continued
